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AbstrAct
Introduction Smoking rates among individuals in 
treatment for opioid addiction are close to five times that 
of the general public. Moreover, drug-addicted smokers 
have a premature mortality rate four times greater than 
drug-addicted non-smokers. The aim of this pilot study 
was to investigate whether contingency management 
(CM) can be successfully added to evidence-based stop 
smoking treatment in individuals undergoing treatment for 
opioid addiction and assess preliminary evidence for its 
impact.
Participants Forty tobacco smokers currently undergoing 
treatment for opioid addiction.
Intervention Escalating with reset CM as an adjunct 
to standard smoking cessation treatment. Financial 
incentives will be administered over a 5-week period for 
either biochemically verified abstinence from smoking or 
attendance at the clinic. Participants will be randomised 
to conditions stratified on current levels of smoking (high 
or low).
Objectives and analyses To assess whether a CM 
intervention can be successfully added to standard stop 
smoking services treatment, in patients undergoing 
outpatient treatment for opioid addiction. This will be 
measured as the number of people completing the 
5 weeks of the intervention.
Ethics and dissemination Ethics approval for the study 
was granted on the 16 June 2016 by the London—city 
and east (reference 16/LO/0990) ethics committee. The 
pilot study was retrospectively registered on  clincaltrials. 
gov in January 2017 (ID: NCT03015597). A SPIRIT 
checklist and figure are available for this protocol. It is 
planned that the results of this study will be published in 
an academic journal.
bAckgrOund
Tobacco smoking is the leading cause of 
premature death in the Western world,1 
currently killing six million people per year 
across the globe, predicted to rise to eight 
million people annually by 2030.2 In England 
alone, smoking killed 74 000 people in 2014.3 
Consequently, tobacco smoking places a 
large economic burden on both the National 
Health Service and the larger UK economy. 
It has been estimated that tobacco smoking 
costs the NHS approximately two billion 
pounds per year, with a total cost to the UK 
economy of approximately 13 billion pounds 
annually.4
In 2016, smoking prevalence in the general 
UK population fell below 17% for the first 
time.5 However, despite this encouraging 
downwards trend, smoking prevalence 
among those in treatment for drug addic-
tion remains high, with a prevalence of 
88% recorded in the UK in 20136 and little 
change observed in the 20 years from 1988 
to 2008.7 Drug-addicted smokers also have 
a fourfold greater premature mortality rate 
than non-smokers.8 This situation is further 
exacerbated by evidence showing that the 
efficacy of the standard stop smoking treat-
ment currently used is nearly halved when 
an individual has used illicit drugs in the past 
30 days.9 There is, therefore, a great need 
for the development of novel interventions 
for tobacco smoking for those in drug addic-
tion treatment that can bolster the efficacy 
of current interventions. One of the highest 
rates of smoking prevalence in substance 
abuse treatment is observed in opioid addic-
tions treatment, ranging between 84% and 
98%.7 10–13 Moreover, those in treatment for 
opioid addiction report high rates of interest 
in stop smoking treatment,10 11 making them 
an ideal population for the development 
of interventions for tobacco smoking in 
substance abuse treatment.
Contingency management (CM) is a 
behavioural intervention based on the prin-
ciples of operant conditioning, whereby 
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strengths and limitations of this study
 ► Extends an extensively tested evidence-based 
intervention to a novel treatment population.
 ► Implements a randomised controlled experimental 
design.
 ► Due to constraints of the intervention, blinding of 
both participants and treatment centre staff is not 
possible.
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changes in behaviour are brought about by positively 
rewarding desired behaviours. CM has been shown to 
be an effective intervention for drug use during opioid 
addiction14 and has been recommended for use in opioid 
addictions in the UK for some time.15 Some studies show 
promising results for CM in smoking cessation during 
treatment for opioid addiction16–20; however, this remains 
under-researched. Moreover, none of the currently 
published studies investigating this were carried out in 
the UK, or alongside standard stop smoking treatment.
The aim of the proposed pilot study was to assess 
whether a CM intervention can be successfully added 
to standard stop smoking services treatment in patients 
undergoing outpatient treatment for opioid addiction.
EthIcs
Risks to participants
There is no known risk associated with the CM behavioural 
intervention. Smoking cessation can precipitate a 
number of uncomfortable withdrawal symptoms. These 
will be attenuated by the stop smoking services treatment 
provided at the treatment centre, an evidence-based treat-
ment that includes nicotine replacement therapy (NRT), 
e-cigarettes and behavioural support. Any information 
recorded from participants will be anonymised using a 
participant ID number, the master sheet for which will be 
stored in a locked cabinet at the treatment centre. This 
ensures that no identifiable information will ever leave 
the treatment centre.
Vouchers rather than cash
The treatment centre where the pilot study is being 
carried out did not want participants to be paid in cash 
so as not be able to buy cigarettes, alcohol or drugs. The 
‘Love2Shop’ vouchers used as an alternative can be spent 
in a number of high street stores. Although cash vouchers 
have been shown to be more effective than vouchers in 
some case,21 other research has shown cash and mone-
tary vouchers to be of equal efficacy.22 23 The use of mone-
tary vouchers, therefore, should not negatively impinge 
on the efficacy of the current intervention. Participants 
will receive both the study intervention and standard stop 
smoking services treatment at no cost.
MEthOds/dEsIgn
This protocol was designed in accordance with the 
SPIRIT (Standard Protocol Items: Recommendations for 
Interventional Trials) statement. See online supplemen-
tary material for SPIRIT checklist and online supplemen-
tary figure.
Objectives
Primary objective: To investigate whether a CM interven-
tion can be successfully added to standard stop smoking 
services treatment, in patients undergoing outpatient 
treatment for opioid addiction, in order to identify any 
elements that need changing before carrying out a full-
scale randomised controlled trial (RCT).
Secondary objective: To gather preliminary findings 
regarding the effects of the CM intervention on smoking 
in this group, and any possible effects the intervention 
may have on opioid addiction treatment outcomes.
Participants, recruitment, inclusion criteria and randomisation
As this is a pilot study, the primary outcome is not the effi-
cacy of the study intervention. Consequently, the sample 
size has not been calculated to ascertain efficacy. Instead, 
the method outlined by Viechtbauer et al24 for calculating 
the sample size based on the probability of any issues that 
may arise has been used. A sample size of 40 using the 
above rationale is powerful enough to provide over 90% 
certainty of detecting any issues that occur with a proba-
bility of over 5%.
The study therefore aims to recruit 40 patients, all 
undergoing current treatment for opioid addiction and 
who smoke ten or more cigarettes a day. Participants 
will be recruited from the study site, an outpatient drug 
addiction treatment centre, either through self-refer-
rals in response to advertisements shown in the treat-
ment centre or referrals from treatment centre staff. 
Participants are eligible for inclusion if they want to quit 
smoking (complete abstinence), are aged between 18 
and 65 years, undergoing pharmacological treatment for 
opioid addiction, smoke a minimum of 10 cigarettes per 
day and provide informed consent. Use of smoking cessa-
tion medication is not a criterion for exclusion. Partici-
pants will be ineligible for inclusion in the study if they 
exhibit insufficient English skills to understand study 
protocols, are currently undergoing treatment for other 
drugs of abuse or if taking part in other research. Preg-
nant women will not be excluded.
Participants will be randomised into either experimental 
(CM for abstinence) or control (CM for attendance) 
conditions when recruited into the trial. Randomisation 
will be performed by the principal investigator (PI), using 
the service provided by the company ‘sealed envelope’,25 
and will be performed using random permuted blocks 
within strata. Randomisation will be stratified based on 
participants’ current smoking frequency (between 10 
and 20 per day, and more than 20 per day6). All partic-
ipants will be given at least 24 hours after being given an 
information sheet to decide whether to take part, and will 
provide written consent, collected by the PI (TSA).
study design
A two-arm randomised controlled pilot study with 6-month 
follow-up. The intervention will be provided as an adjunct 
to the standard smoking cessation treatment provided at 
the treatment centre, with CM rewards available during 
2–5 weeks of the smoking cessation treatment. The study 
will be conducted in compliance with the principles of the 
Declaration of Helsinki,26 the principles of Good Clinical 
Practice and all applicable regulatory requirements.
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Table 1 Reward schedule
Smoking cessation 
treatment week No
1 2 3 4 5 6
CM week No 1 2 3 4 5
Reward value £0.00 £5.00 £10.00 £20.00 £40.00 £40.00
Reward schedule for a participant that remains abstinent and/or attends all smoking cessation treatment meetings (dependent on condition) 
for the duration of the intervention. Maximum total reward: £115.
CM, contingency management.
Opioid treatment
As part of the standard opioid treatment programme, the 
clinic offers both behavioural and pharmacological treat-
ments. Pharmacological treatments include methadone, 
buprenorphine and in some cases a combination of 
buprenorphine and naloxone; each of these progresses 
from a daily supervised dose, to a daily unsupervised 
pickup to a weekly unsupervised pickup. All medica-
tion prescriptions are reviewed every 6 months. Clients 
are also allocated a key worker with whom they meet 
in person every 2 weeks to discuss their treatment, and 
who can refer them to a number of different behavioural 
support programmes. These include psychological thera-
pies or group therapy for their drug use, or a number of 
other services for issues related to their drug use such as 
needle exchanges, bloodborne virus testing and domestic 
violence support. In the past, the clinic has implemented 
CM interventions as part of other research projects; 
however, CM has never been implemented as part of the 
standard opioid treatment programme.
standard treatment
Prior to the initiation of this study, the smoking clinic 
had not operated for several months; smoking cessation 
training was therefore readministered to clinic staff and 
the smoking cessation treatment relaunched prior to the 
start of the trial. The treatment runs at the same time 
each week, on a Monday afternoon between 2 and 4 PM. 
The standard smoking cessation treatment provided at 
the treatment centre follows the treatment programme 
set out by the National Centre for Smoking Cessation 
and Training (NCSCT)27 and The National Institute 
for Health and Care Excellence (NICE) guidelines for 
smoking cessation.28 This treatment combines manual-
ised behavioural support to stop smoking with NRT and 
takes place over 6 weeks with one session per week. In 
the context of drug addiction treatment, service users 
are sometimes offered treatment over a slightly longer 
period of time. In the first meeting, the service user’s 
readiness and ability to quit is assessed, information for 
the remainder of the treatment programme is given and 
a quit date for the next week is set. For the remaining 
5 weeks, clients attend the clinic to receive behavioural 
support and have their abstinence biochemically verified. 
In the study clinic, NRT is available free of charge to all 
individuals engaged with smoking cessation treatment, in 
the form of nicotine patches, gum, inhalators, mouth or 
oral spray and oral strips. At the time of the study, the 
clinic is also additionally offering (on a trial basis) e-ciga-
rettes, which have a nicotine content of 18 mg/ml. These 
e-cigarettes are disposable and securely sealed, initially 
designed for use in high-security environments such as 
prisons.29 The smoking cessation treatment provided at 
the treatment centre does not include treatment with 
bupropion.
During the 6 weeks of treatment, service users are 
given a week’s supply of NRT or e-cigarettes at a time. At 
the end of the 6 weeks, service users are given a further 
2-week supply of NRT or e-cigarettes before exiting the 
treatment. The type of NRT received is decided by clients 
with guidance from the cessation worker, and can consti-
tute a single form of NRT or a combination of different 
types. Clients’ breath carbon monoxide (CO) levels are 
measured using a Bedfont piCO+ Smokerlyzer breath CO 
monitor. Measurements are taken at the initial visit and at 
each subsequent visit over the next 5 weeks, to biochem-
ically verify self-reported abstinence from smoking 
(CO<10 ppm30). NRT and e-cigarette use is recorded 
throughout treatment. Participants are made aware of 
these procedures in the participant information sheet 
that they are given prior to signing consent to the study 
(see online supplementary appendix 1).
cM intervention
The CM intervention will run as an adjunct to the 
normal smoking cessation treatment, and follows an 
escalating with reset schedule. In escalating with reset 
CM, rewards increase in a set increment value for each 
successive verified display of the desired behaviour. 
When the desired behaviour is not observed, no reward 
is given, and the reward value for the next verified 
display of the desired behaviour is reset to that of the 
initial reward. Reward values then begin to rise again in 
the same way as before. The CM intervention will run 
for 5 weeks in total, starting in week 2 of the standard 
stop smoking services treatment and ending in week 
6 (table 1). Randomisation will be performed after 
collection of demographics following taking of consent. 
Participants will be rewarded for smoking abstinence 
in the experimental condition, or for attending the 
smoking cessation clinic in the control condition. 
Smoking abstinence will be defined as a breath CO 
reading of <10 ppm, and attendance will be defined 
as attending the smoking cessation treatment at the 
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clinic that week. After each smoking cessation treat-
ment session, the cessation worker will fill out a slip 
that records each participant’s individual participant 
number and his or her breath CO for that day. The 
cessation worker will give these slips to the PI who will 
sit in an adjacent room and administer rewards where 
appropriate. All participant data will be recorded using 
participant numbers ensuring that no identifiable data 
leave the clinic, and will be stored in an encrypted file, 
separate to a sheet matching participant names to IDs 
which will be kept in a locked office at the treatment 
centre. Due to the nature of the CM intervention, it is 
not possible to blind participants to treatment alloca-
tion. Cessation workers will not be made aware of treat-
ment allocation; however, they cannot be considered to 
be blinded to treatment allocation as it is possible that 
clients may discuss this with them.
Reward values will be the same in both conditions 
and begin at £5, doubling each time the incentivised 
behaviour is recorded to a maximum of £40. All rewards 
will be given as ‘Love2Shop’ vouchers. Over the course of 
the whole intervention, participants will be able to earn a 
maximum of £115 (table 1). At the end of the CM inter-
vention, participants will be asked to complete a client 
satisfaction and well-being survey, which was previously 




The primary outcome will be assessed by recording the 
number of participants completing the 5 weeks of the 
intervention in each condition. Success will be defined as 
60% or more of participants completing treatment.
The secondary objectives of the study are to gather 
preliminary findings regarding the effects of the CM inter-
vention on smoking in this group, and any possible effects 
the intervention may have on opioid addiction treatment 
outcomes. Smoking abstinence will be recorded as point 
prevalence and biochemically verified with abstinence 
defined as a breath CO reading of under 10 ppm30.
Participants were informed that smoking cannabis would 
increase CO levels.
Participant medical records will be accessed after 
completion of the intervention to ascertain participants’ 
opioid addiction treatment, including treatment adher-
ence, drug types (methadone, Subutex, so on), dosage 
and schedule (daily supervised pickup, weekly pickup, 
so on) as well as illicit drug use throughout the period of 
the trial.
Follow-up measures
At the 6-month follow-up (see below for follow-up proce-
dures), the following measures will be recorded:
Point prevalence smoking abstinence: Self-reported 
smoking abstinence for 7-days before follow-up and 
exhaled air CO<10 ppm.30
Continuous abstinence: Self-reported smoking absti-
nence since end of treatment and exhaled air CO<10 ppm. 
Participants smoking five or fewer cigarettes during 
the 6-month follow-up will be considered self-reported 
quitters.30
Illicit drug use, collected at the end of the study from 
participants’ medical records.
All those lost to follow-up will be treated as smoking.30
Other measures
At the first stop smoking treatment session, a number 
of demographic and smoking behaviour variables will 
be recorded. The collection form for this informa-
tion is shown in online supplementary appendix 2. 
As many contact details as possible will also be taken 
for the participants in order to increase the proba-
bility of participants being able to be followed-up. This 
will include the details of relevant friends and family 
members. Participants will also complete a satisfaction 
questionnaire on the last day of their participation 
in the trial, which will assess a number of satisfaction 
criteria including the value of incentives received (see 
online supplementary appendix 3).
Follow-up procedures
Six months after their set quit date, participants will 
be contacted by the PI to ascertain their self-reported 
smoking status. The main purpose of this follow-up is 
to ascertain whether participants can be successfully 
followed-up for 6 months, and no group differences are 
expected to be found between the different conditions. 
To test the optimal follow-up method, participants 
will be pseudo-randomised by recruitment order to be 
contacted by text and phone call, or email and phone 
call. All participants will also be asked to return to the 
clinic in order to have their breath CO levels tested to 
verify abstinence. Once this is done, participants will 
have completed their participation in the study. Partic-
ipants will receive a £10 voucher for completing the 
follow-up procedure.
Planned analysis
As the primary objective of the intervention does not 
entail any hypothesis testing, the only statistics reported 
for this will be descriptive, namely means and SD for 
the number of participants retained at the end of treat-
ment in each condition. Baseline demographics will be 
compared between conditions using t-tests for contin-
uous and χ2 test for categorical data to ensure that any 
differences in these are not driving any potential differ-
ences in retention.
For the secondary objectives, differences between the 
groups in smoking cessation will be investigated using 
χ2 test, differences between conditions on opioid use 
and opioid treatment during the intervention will be 
compared using t-tests and χ2 tests dependent on data and 
any questionnaire data will be reported using descriptive 
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statistics. All statistics will be performed as two-tailed tests 
using an alpha value of 0.05.
dIscussIOn
The addition of contingent incentives to standard 
evidence-based smoking cessation treatment in opiate 
addiction clients will be an innovative approach, having 
never been attempted before in the UK.
The current trial has a number of limitations that 
should be improved in future studies. First, the value 
and frequency of rewards in this study are comparatively 
lower than those of previous trials and should, there-
fore, be increased to encourage the cessation. The use of 
breath CO only in measuring abstinence is not the most 
rigorous method available for testing, due to the rela-
tively short period of time it takes for breath CO levels 
to return to levels considered as those of a non-smoker. 
Urine cotinine levels provide a more rigorous measure of 
abstinence; however, they are confounded by the use of 
NRT, therefore necessitating the measurement of anab-
asine instead. The measurements of both cotinine and 
anabasine were beyond the scope of the current interven-
tion. Furthermore, provision of incentives to participants 
in the attendance group should come before breath CO 
levels are measures to avoid the risk of these participants 
thinking their incentives are linked to CO levels.
However, the intervention has a number of potential 
strengths. If feasible, the intervention will be easily dissem-
inated, and it has the potential to be an effective inter-
vention for smoking in this client group. Pilot studies are 
an imperative step in the development of complex inter-
ventions, and form the first step on the road to full-scale 
RCT and potentially implementation.32 33 If successful, 
this programme paves the way for the development of 
a full-scale RCT of CM for smoking in opiate addiction 
treatment, which would include an economic evaluation, 
and potential trials for smokers in other drug addiction 
treatment.
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